Human papillomavirus therapy for the prevention and treatment of cervical cancer

被引：3
作者：
Samir N. Khleif
机构：
[1] Center for Cancer Research, National Cancer Institute, National Naval Medical Center, Building 8, Room 4137, Bethesda, 20892, MD
来源：
Current Treatment Options in Oncology | 2003年 / 4卷 / 2期
关键词：
Cervical Cancer; Cervical Cancer Cell; Cervical Intraepithelial Neoplasia; Hairpin Ribozyme; Recombinant Vaccinia Virus;
D O I：
10.1007/s11864-003-0012-0
中图分类号：
学科分类号：
摘要：
Cervical carcinoma is associated with human papillomavirus infection. Proliferation of cancer cells depends on the continual expression of the E6 and E7 viral oncogenes. This article includes treatment strategies that can interfere with expression or function of the proteins and immunotherapeutic approaches that can eliminate cells that express E6 and E7 proteins. © 2003, Current Science Inc.
引用
收藏
页码：111 / 119
页数：8
相关论文
共 66 条
  • [21] Jin L., Qi M., Chen D.Z., Et al., Indole-3-carbinol prevents cervical cancer in human papilloma virus type 16 (HPV16) transgenic mice, Cancer Res, 59, pp. 3991-3997, (1999)
  • [22] Kamradt M.C., Mohideen N., Vaughan A.T., RU486 increases radiosensitivity and restores apoptosis through modulation of HPV E6/E7 in dexamethasone-treated cervical carcinoma cells, Gynecol Oncol, 77, pp. 177-182, (2000)
  • [23] Maehama T., Patzelt A., Lengert M., Et al., Selective downregulation of human papillomavirus transcription by 2-deoxyglucose, Int J Cancer, 76, pp. 639-646, (1998)
  • [24] Narayanan B.A., Holladay E.B., Nixon D.W., Mauro C.T., The effect of all-trans and 9-cis retinoic acid on the steady state level of HPV16 E6/E7 mRNA and cell cycle in cervical carcinoma cells, Life Sci, 63, pp. 565-573, (1998)
  • [25] Hietanen S., Lain S., Krausz E., Et al., Activation of p53 in cervical carcinoma cells by small molecules, Proc Natl Acad Sci U S A, 97, pp. 8501-8506, (2000)
  • [26] Scribner D.R., Benbrook D.M., Retinoids enhance cisplatin-based chemoradiation in cervical cancer cells in vitro, Gynecol Oncol, 85, pp. 223-225, (2002)
  • [27] Follen M., Atkinson E.N., Schottenfeld D., Et al., A randomized clinical trial of 4-hydroxyphenylretinamide for high-grade squamous intraepithelial lesions of the cervix, Clin Cancer Res, 7, pp. 3356-3365, (2001)
  • [28] Wadler S., Schwartz E.L., Anderson P., Et al., Preliminary phase II clinical and pharmacokinetic study of 9-cis retinoic acid in advanced cervical cancer. New York Gynecologic Oncology Group, Cancer J Sci Am, 5, pp. 165-170, (1999)
  • [29] DeLong R., Nolting A., Fisher M., Et al., Comparative pharmakokinetics, tissue distribution, and tumor accumulation of phosphorothioate, phosphorodithioate, and methylphosphonate oligonucleatide in nude mice, Antisense Nucleic Acid Drug Dev, 7, pp. 71-77, (1997)
  • [30] Crook T., Tidy J.A., Vousden K.H., Degradation of p53 can be targeted by HPV E6 sequences distinct from those required for p53 binding and trans-activation, Cell, 67, pp. 547-556, (1991)
1234567